Global Immuno-Oncology Assays Market (2021 to 2026) - Growing Significance of Companion Diagnostics Presents Opportunities


Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026" report has been added to's offering.

The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5% during the forecast period.

Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand, the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market.

The consumables segment accounted for the highest growth rate in the immuno-oncology assays market, by product & service, during the forecast period

The immuno-oncology assays market is segmented into consumables, instruments, and software & services based on product & service. In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market. The requirement of consumables in large numbers as compared to instruments is the major factor contributing to the growth of this segment.

The research applications segment accounted for the highest CAGR

Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics. In 2020, the research applications segment accounted for the highest growth rate. This can be attributed to the rising prominence of biomarker-based drug development.

Asia Pacific: The fastest-growing region immuno-oncology assays market

The global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centered on China and Japan. Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Immuno-Oncology Assays Market Overview
4.2 Immuno-Oncology Assays Market Share, by Product & Service, 2021 Vs. 2026
4.3 Immuno-Oncology Assays Market Share, by Technology, 2021 Vs. 2026
4.4 Immuno-Oncology Assays Market Share, by Indication, 2021 Vs. 2026
4.5 Immuno-Oncology Assays Market Share, by Application, 2021 Vs. 2026
4.6 Immuno-Oncology Assays Market: Geographic Growth Opportunities

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers Rising Incidence of Cancer and Growing Adoption of Targeted Therapies Increased Demand for Personalized Medicine
5.2.2 Restraints Requirement of High Capital Investments and Low Cost-Benefit Ratio Unfavorable Regulatory and Reimbursement Scenario High Cost of Immunotherapy
5.2.3 Opportunities Emerging Markets Offer Lucrative Opportunities Growing Significance of Companion Diagnostics
5.2.4 Challenges Low Awareness of Cancer Immunotherapy
5.3 Impact of COVID-19 on the Immuno-Oncology Assays Market
5.4 Pricing Analysis
5.5 Patent Analysis
5.6 Trade Analysis
5.6.1 Trade Analysis for Diagnostic and Laboratory Reagents
5.7 Value Chain Analysis
5.8 Supply Chain Analysis
5.9 Ecosystem Analysis of the Immuno-Oncology Assays Market
5.10 Porter's Five Forces Analysis
5.10.1 Threat of New Entrants
5.10.2 Threat of Substitutes
5.10.3 Bargaining Power of Buyers
5.10.4 Bargaining Power of Suppliers
5.10.5 Degree of Competition
5.11 PESTLE Analysis
5.12 Regulatory Landscape
5.12.1 North America US Canada
5.12.2 Europe
5.12.3 Asia-Pacific Japan India
5.12.4 Latin America Brazil Mexico
5.12.5 Middle East
5.12.6 Africa
5.13 Technology Analysis
5.14 Yc-Ycc Shift
5.14.1 Yc-Ycc Shift for the Immuno-Oncology Assays Market

6 Immuno-Oncology Assays Market, by Product & Service
6.1 Introduction
6.2 Consumables
6.2.1 Recurrent Purchase of Kits is a Major Factor Driving Market Growth
6.3 Instruments
6.3.1 Launch of Technologically Advanced Products to Support Market Growth
6.4 Software & Services
6.4.1 Increasing Need to Deliver Accurate and Timely Analysis of Diagnostic Tests to Support Market Growth

7 Immuno-Oncology Assays Market, by Technology
7.1 Introduction
7.2 Polymerase Chain Reaction
7.2.1 Emergence of Advanced Pcr Technologies to Support Market Growth
7.3 Immunoassay
7.3.1 Immunoassays Have the Potential to Reduce Cancer Mortality Rate by Facilitating the Diagnosis of Cancer at an Early Stage
7.4 Next-Generation Sequencing
7.4.1 Ngs Segment to Grow at the Highest CAGR During the Forecast Period
7.5 in Situ Hybridization
7.5.1 High Demand for in Situ Hybridization in the Diagnosis of Small Tumors to Drive Market Growth
7.6 Flow Cytometry
7.6.1 Growing Incidence & Prevalence of Cancer to Support Market Growth

8 Immuno-Oncology Assays Market, by Indication
8.1 Introduction
8.2 Lung Cancer
8.2.1 Increasing Research on Lung Cancer Biomarkers to Drive Market Growth
8.3 Breast Cancer
8.3.1 Increasing Government Funding for Breast Cancer Research to Drive Market Growth
8.4 Colorectal Cancer
8.4.1 Increasing Prevalence of Colorectal Cancer to Propel Market Growth
8.5 Bladder Cancer
8.5.1 Bladder Cancer Segment to Witness Slower Growth Owing to the Limited Adoption of Immuno-Oncology Assays
8.6 Melanoma
8.6.1 Growing Incidence of Melanoma to Drive the Demand for Immuno-Oncology Assays
8.7 Other Cancers

9 Immuno-Oncology Assays Market, by Application
9.1 Introduction
9.2 Research Applications
9.2.1 Rising Prominence of Biomarker-Based Drug Development to Drive the Research Applications Market
9.3 Clinical Diagnostics
9.3.1 Benefits of Immuno-Oncology Assays are Driving Their Adoption in Clinical Diagnostics

10 Immuno-Oncology Assays Market, by Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Latin America
10.6 Middle East & Africa

11 Competitive Landscape
11.1 Overview
11.2 Key Player Strategies
11.3 Revenue Share Analysis of Top Market Players
11.4 Market Share Analysis
11.5 Company Evaluation Quadrant
11.5.1 List of Evaluated Vendors
11.5.2 Stars
11.5.3 Emerging Leaders
11.5.4 Pervasive Players
11.5.5 Participants
11.6 Competitive Leadership Mapping for Startups/Smes (2020)
11.6.1 Progressive Companies
11.6.2 Starting Blocks
11.6.3 Responsive Companies
11.6.4 Dynamic Companies
11.7 Product and Geographical Footprint Analysis of Top Players
11.8 Competitive Scenario
11.8.1 Market Evaluation Framework, 2018-2020
11.8.2 Product Launches & Regulatory Approvals
11.8.3 Deals
11.8.4 Other Developments

12 Company Profiles
12.1 Key Players
12.1.1 Thermo Fisher Scientific, Inc.
12.1.2 F. Hoffmann-La Roche Ltd.
12.1.3 Illumina, Inc.
12.1.4 Merck Millipore
12.1.5 Agilent Technologies, Inc.
12.1.6 Abbott Laboratories, Inc.
12.1.7 Sartorius Ag
12.1.8 Nanostring Technologies, Inc.
12.1.9 Htg Molecular Diagnostics, Inc.
12.1.10 Perkinelmer, Inc.
12.1.11 Qiagen N.V.
12.2 Other Players
12.2.1 Biomerieux Sa
12.2.2 Myriad Genetics, Inc.
12.2.3 Guardant Health, Inc.
12.2.4 Bio-Rad Laboratories, Inc.
12.2.5 Charles River Laboratories, Inc.
12.2.6 Seegene Inc.
12.2.7 Meso Scale Diagnostics, LLC.
12.2.8 Olink
12.2.9 Asuragen, Inc.
12.2.10 Invivoscribe, Inc.
12.2.11 Creative Biolabs
12.2.12 Reachbio LLC
12.2.13 Nmi Technologietransfer GmbH

13 Appendix
13.1 Insights from Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: The Subscription Portal
13.4 Available Customizations

For more information about this report visit


Contact Data